EGFR and metastatic colorectal cancer: The primary objective of the present study was to determine the maximum tolerated dose (MTD) of motesanib when administered in combination with the fully human anti-EGFR monoclonal antibody panitumumab, which is approved for the treatment of metastatic colorectal cancer, and the chemotherapies gemcitabine and cisplatin in patients with advanced solid tumors.